Payment overview · 2025
General Payments
$606.27
33 reported records · 15 companies
Healthcare provider profile · identity verified
Chris E Mcgee, MD
Allopathic & Osteopathic Physicians|Family Medicine · DECATUR, TX · NPI 1487659439
Verified facts
What the public records show
CMS Open Payments records show Chris E Mcgee, MD received $606.27 in general payments during 2025 across 33 reported records.
Abbott Laboratories accounted for 18.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 228 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $111.03 | 18.3% | 5 | 2025 |
| MIMEDX Group, Inc. | Unresolved — no canonical attribution shown | $73.41 | 12.1% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $63.42 | 10.5% | 4 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $55.43 | 9.1% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $48.58 | 8.0% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $45.67 | 7.5% | 3 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $45.48 | 7.5% | 2 | 2025 |
| Optinose US, Inc. | Unresolved — no canonical attribution shown | $42.11 | 7.0% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $26.52 | 4.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $20.19 | 3.3% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.07 | 3.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.25 | 2.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.25 | 2.5% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $14.13 | 2.3% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $11.73 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $606.27 | 33 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $63.42 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $63.42 | 4 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $55.43 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $45.67 | 3 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $45.48 | 2 | 2025 |
Source payment records
|
|||||
| Xhance Normalized: xhance |
Drug | Optinose US, Inc. | $42.11 | 2 | 2025 |
Source payment records
|
|||||
| AVEIR Normalized: aveir |
Device | Abbott Laboratories | $33.31 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $31.49 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $27.17 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $27.17 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $26.52 | 1 | 2025 |
Source payment records
|
|||||
| ETERNA Normalized: eterna |
Device | Abbott Laboratories | $24.35 | 1 | 2025 |
Source payment records
|
|||||
| PROCLAIM Normalized: proclaim |
Device | Abbott Laboratories | $21.88 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $21.41 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $20.19 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $20.19 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $18.07 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.25 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $15.25 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $15.25 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $14.13 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $11.73 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 63 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 228 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 18 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
32 | 16 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
21 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
53 | 29 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
22 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
37 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
53 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
63 | 28 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
228 | 83 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
18 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
140 | 53 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 495 | 285 |
| Atorvastatin Calcium | Atorvastatin Calcium | 490 | 265 |
| Lisinopril | Lisinopril | 404 | 215 |
| Pantoprazole Sodium | Pantoprazole Sodium | 390 | 199 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 367 | 65 |
| Amlodipine Besylate | Amlodipine Besylate | 334 | 169 |
| Gabapentin | Gabapentin | 311 | 171 |
| Losartan Potassium | Losartan Potassium | 251 | 136 |
| Trazodone Hcl | Trazodone Hcl | 235 | 131 |
| Metoprolol Succinate | Metoprolol Succinate | 232 | 123 |
| Ozempic | Semaglutide | 228 | 83 |
| Montelukast Sodium | Montelukast Sodium | 218 | 124 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 212 | 116 |
| Duloxetine Hcl | Duloxetine Hcl | 208 | 107 |
| Metformin Hcl | Metformin Hcl | 206 | 118 |
| Tamsulosin Hcl | Tamsulosin Hcl | 195 | 95 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 186 | 97 |
| Omeprazole | Omeprazole | 178 | 103 |
| Methylprednisolone | Methylprednisolone | 175 | 149 |
| Sertraline Hcl | Sertraline Hcl | 167 | 82 |
| Carvedilol | Carvedilol | 162 | 87 |
| Furosemide | Furosemide | 160 | 94 |
| Tramadol Hcl | Tramadol Hcl | 160 | 48 |
| Hydrochlorothiazide | Hydrochlorothiazide | 154 | 92 |
| Alprazolam | Alprazolam | 145 | 37 |
| Eliquis | Apixaban | 140 | 53 |
| Potassium Chloride | Potassium Chloride | 134 | 74 |
| Prednisone | Prednisone | 133 | 104 |
| Meloxicam | Meloxicam | 126 | 79 |
| Tizanidine Hcl | Tizanidine Hcl | 125 | 47 |
| Escitalopram Oxalate | Escitalopram Oxalate | 123 | 65 |
| Pravastatin Sodium | Pravastatin Sodium | 117 | 60 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 116 | 108 |
| Bupropion Xl | Bupropion Hcl | 111 | 49 |
| Clopidogrel | Clopidogrel Bisulfate | 107 | 65 |
| Azithromycin | Azithromycin | 105 | 98 |
| Buspirone Hcl | Buspirone Hcl | 105 | 55 |
| Quetiapine Fumarate | Quetiapine Fumarate | 103 | 46 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 102 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 102 | 60 |
| Alendronate Sodium | Alendronate Sodium | 95 | 44 |
| Citalopram Hbr | Citalopram Hydrobromide | 89 | 54 |
| Zolpidem Tartrate | Zolpidem Tartrate | 89 | 18 |
| Clonazepam | Clonazepam | 88 | 18 |
| Simvastatin | Simvastatin | 84 | 45 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 80 | 54 |
| Methocarbamol | Methocarbamol | 78 | 48 |
| Pregabalin | Pregabalin | 77 | 27 |
| Baclofen | Baclofen | 75 | 25 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 73 | 34 |
| Celecoxib | Celecoxib | 73 | 43 |
| Spironolactone | Spironolactone | 72 | 38 |
| Glipizide | Glipizide | 71 | 44 |
| Mirtazapine | Mirtazapine | 71 | 37 |
| Allopurinol | Allopurinol | 67 | 36 |
| Myrbetriq | Mirabegron | 65 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 64 | 40 |
| Estradiol | Estradiol | 63 | 30 |
| Mounjaro | Tirzepatide | 63 | 28 |
| Ropinirole Hcl | Ropinirole Hcl | 61 | 33 |
| Fenofibrate | Fenofibrate | 59 | 29 |
| Metformin Hcl Er | Metformin Hcl | 59 | 30 |
| Aripiprazole | Aripiprazole | 58 | 30 |
| Doxycycline Hyclate | Doxycycline Hyclate | 58 | 51 |
| Levofloxacin | Levofloxacin | 58 | 44 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 58 | 33 |
| Lamotrigine | Lamotrigine | 55 | 25 |
| Fluconazole | Fluconazole | 54 | 47 |
| Warfarin Sodium | Warfarin Sodium | 54 | 15 |
| Farxiga | Dapagliflozin Propanediol | 53 | 29 |
| Jardiance | Empagliflozin | 53 | 25 |
| Famotidine | Famotidine | 52 | 29 |
| Ondansetron Hcl | Ondansetron Hcl | 52 | 27 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 52 | 21 |
| Doxepin Hcl | Doxepin Hcl | 50 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 50 | 26 |
| Glimepiride | Glimepiride | 49 | 29 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 48 | 44 |
| Oxycodone Hcl | Oxycodone Hcl | 46 | suppressed |
| Atenolol | Atenolol | 45 | 22 |
| Ondansetron Odt | Ondansetron | 45 | 38 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 44 | 37 |
| Ezetimibe | Ezetimibe | 43 | 19 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 41 | 40 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 41 | 24 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 41 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 40 | 25 |
| Glipizide Er | Glipizide | 40 | 19 |
| Lorazepam | Lorazepam | 40 | 12 |
| Xarelto | Rivaroxaban | 40 | 15 |
| Clonidine Hcl | Clonidine Hcl | 39 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 39 | 22 |
| Eszopiclone | Eszopiclone | 39 | 12 |
| Topiramate | Topiramate | 39 | 23 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 38 | 23 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 37 | 15 |
| Clindamycin Hcl | Clindamycin Hcl | 36 | 33 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 36 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 36 | 16 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 36 | 12 |
| Valacyclovir | Valacyclovir Hcl | 36 | 20 |
| Amitriptyline Hcl | Amitriptyline Hcl | 34 | 19 |
| Dicyclomine Hcl | Dicyclomine Hcl | 34 | 19 |
| Promethazine Hcl | Promethazine Hcl | 34 | 21 |
| Propranolol Hcl | Propranolol Hcl | 34 | 13 |
| Sumatriptan Succinate | Sumatriptan Succinate | 34 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 34 | 24 |
| Amoxicillin | Amoxicillin | 33 | 31 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 33 | 14 |
| Oxybutynin Chloride | Oxybutynin Chloride | 33 | 18 |
| Valsartan | Valsartan | 33 | 15 |
| Diazepam | Diazepam | 32 | suppressed |
| Ibuprofen | Ibuprofen | 32 | 20 |
| Linzess | Linaclotide | 32 | 16 |
| Cefdinir | Cefdinir | 31 | 29 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | 17 |
| Finasteride | Finasteride | 31 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 31 | 15 |
| Levetiracetam | Levetiracetam | 31 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | 12 |
| Prazosin Hcl | Prazosin Hcl | 30 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 29 | 16 |
| Donepezil Hcl | Donepezil Hcl | 29 | 14 |
| Fentanyl | Fentanyl | 29 | suppressed |
| Temazepam | Temazepam | 29 | 11 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 29 | 17 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 28 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 28 | 12 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 27 | suppressed |
| Cephalexin | Cephalexin | 27 | 27 |
| Lovastatin | Lovastatin | 27 | 17 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 24 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 22 | 11 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 22 | 11 |
| Azelastine Hcl | Azelastine Hcl | 21 | 13 |
| Metoclopramide Hcl | Metoclopramide Hcl | 21 | 11 |
| Morphine Sulfate Er | Morphine Sulfate | 21 | suppressed |
| Synthroid | Levothyroxine Sodium | 21 | 13 |
| Nifedipine Er | Nifedipine | 20 | 15 |
| Testosterone Cypionate | Testosterone Cypionate | 20 | suppressed |
| Anastrozole | Anastrozole | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Gemfibrozil | Gemfibrozil | 18 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 18 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Rybelsus | Semaglutide | 18 | 12 |
| Sucralfate | Sucralfate | 18 | 12 |
| Carisoprodol | Carisoprodol | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 17 | suppressed |
| Premarin | Estrogens, Conjugated | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | 12 |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Colchicine | Colchicine | 16 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Telmisartan | Telmisartan | 15 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Lubiprostone | Lubiprostone | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Nystatin | Nystatin | 12 | 11 |
| Ramipril | Ramipril | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Focalin Xr | Dexmethylphenidate Hcl | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $606.27 · 33 records | Abbott Laboratories | AIRSUPRA, AREXVY, AVEIR, Auvelity, Cologuard Collection Kit, ETERNA, FREESTYLE LIBRE 3, GEMTESA, INSPIRE, Korlym, MOUNJARO, NURTEC ODT, Ozempic, PREVNAR 20, PROCLAIM, Rybelsus, SHINGRIX, VOQUEZNA, VRAYLAR, Xhance, ZAVZPRET, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error